MedTrace Logo

Novel Regimens in COVID-19 Treatment

NCT04382846 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2020-12-04

No results posted yet for this study

Summary

Nitazoxanide has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.

Conditions

  • COVID
  • Corona Virus Infection

Interventions

DRUG

Nitazoxanide

Nitazoxanide

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • sherief Abd-Elsalam, Ass. Prof. · ass. Prof. Tropical Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-08
Primary Completion
2030-12-01
Completion
2030-12-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04382846 on ClinicalTrials.gov